ArticleThe Journal of experimental medicine2021
JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- PD-1 Inhibits CD4+ TRM-Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A pan-cancer single cell landscape reveals heterogeneity and functional diversity of double-negative T cells.Molecular cancer · 2026Article
- The prognostic significance of JAML and its role in remodeling the immune microenvironment via the cGAS-STING pathway in endometrial cancer.Frontiers in immunology · 2026Article
- The Expression Pattern of the Splice Variants of Coxsackievirus and Adenovirus Receptor Impacts CV-B3-Induced Encephalitis and Myocarditis in Neonatal Mice.International journal of molecular sciences · 2025Article
- Targeted activation of junctional adhesion molecule-like proteinChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Molecular Insights into Cell-Mediated Immunity in Atypical Non-Ulcerated Cutaneous Leishmaniasis.Microorganisms · 2025Article
- Uncovering a new mechanism of ischemic stroke: a study of the association between γδ T cells and immunoinflammation.Frontiers in immunology · 2025Review
- The distinct biological role of JAML positions it as a promising target for treating human cancers and a range of other diseases.Frontiers in immunology · 2025Review
- Cancer immunotherapy by γδ T cells.Science (New York, N.Y.) · 2024Review
- Intraepithelial Lymphocytes of the Intestine.Annual review of immunology · 2024Review
- JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment.In vitro cellular & developmental biology. Animal · 2024Article
- The junctional adhesion molecule-like protein (JAML) is important for the inflammatory response during contact hypersensitivity.Contact dermatitis · 2023Article
- Contributions of coxsackievirus adenovirus receptor to tumorigenesis.Biochemical Society transactions · 2023Article
- Article
- JAML promotes acute kidney injury mainly through a macrophage-dependent mechanism.JCI insight · 2022Article
- CAR Co-Operates With Integrins to Promote Lung Cancer Cell Adhesion and Invasion.Frontiers in oncology · 2022Article
- Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma.Computational and structural biotechnology journal · 2022Article
- γδ T cell costimulatory ligands in antitumor immunity.Exploration of immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
T cells are critical mediators of antitumor immunity and a major target for cancer immunotherapy. Antibody blockade of inhibitory receptors such as PD-1 can partially restore the activity of tumor-infiltrating lymphocytes (TILs). However, the activation signals required to promote TIL responses are less well characterized. Here we show that the antitumor activity of CD8 and γδ TIL is supported by interactions between junctional adhesion molecule-like protein (JAML) on T cells and its ligand coxsackie and adenovirus receptor (CXADR) within tumor tissue. Loss of JAML through knockout in mice resulted in accelerated tumor growth that was associated with an impaired γδ TIL response and increased CD8 TIL dysfunction. In mouse tumor models, therapeutic treatment with an agonistic anti-JAML antibody inhibited tumor growth, improved γδ TIL activation, decreased markers of CD8 TIL dysfunction, and significantly improved response to anti-PD-1 checkpoint blockade. Thus, JAML represents a novel therapeutic target to enhance both CD8 and γδ TIL immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.